retatrutide type 2 diabetes trial results 2024 phase 2 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Summary of the highest percent

Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers

GLP-1 is also consistent with the conclusion that GLP-1 can inhibit liver lipid synthesis [51]

Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program

Medication is just one part of your journey

Understanding the factors that influence an individuals response, such as baseline BMI, sex, and comorbidities, will be crucial in guiding the selection of the most appropriate treatment approach

Stomach problems, sometimes severe, have been reported in people who use Wegovy